Go Pro
→ Iran War Shock: What I Was Told In That Private Meeting (From Banyan Hill Publishing) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
$237.10
+0.2%		$262.62
$197.81
▼
$495.55
$31.65B0.32.00 million shs1.85 million shs
Biogen Inc. stock logo
BIIB
Biogen
$218.50
-1.4%		$207.81
$131.52
▼
$222.85
$32.73B0.17784,147 shs517,409 shs
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
$533.76
-1.8%		$526.96
$393.61
▼
$615.00
$12.56B-1.01321,180 shs268,664 shs
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
$207.88
-6.0%		$193.33
$37.56
▼
$224.31
$47.40B1.391.80 million shs2.00 million shs
7 Best Space Stocks to Own in 2026 Cover
7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
+0.23%+0.37%-17.28%-21.48%-47.80%
Biogen Inc. stock logo
BIIB
Biogen
-1.35%+0.79%+4.33%+11.48%+60.24%
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
-1.83%+3.29%-2.40%+7.34%+25.57%
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
-6.00%-0.75%+14.90%+32.00%+446.48%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
$237.10
+0.2%		$262.62
$197.81
▼
$495.55
$31.65B0.32.00 million shs1.85 million shs
Biogen Inc. stock logo
BIIB
Biogen
$218.50
-1.4%		$207.81
$131.52
▼
$222.85
$32.73B0.17784,147 shs517,409 shs
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
$533.76
-1.8%		$526.96
$393.61
▼
$615.00
$12.56B-1.01321,180 shs268,664 shs
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
$207.88
-6.0%		$193.33
$37.56
▼
$224.31
$47.40B1.391.80 million shs2.00 million shs
7 Best Space Stocks to Own in 2026 Cover
7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
+0.23%+0.37%-17.28%-21.48%-47.80%
Biogen Inc. stock logo
BIIB
Biogen
-1.35%+0.79%+4.33%+11.48%+60.24%
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
-1.83%+3.29%-2.40%+7.34%+25.57%
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
-6.00%-0.75%+14.90%+32.00%+446.48%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
2.92
Moderate Buy$386.1462.86% Upside
Biogen Inc. stock logo
BIIB
Biogen
2.58
Moderate Buy$227.794.25% Upside
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
2.78
Moderate Buy$699.6431.08% Upside
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
2.95
Moderate Buy$198.89-4.32% Downside

Current Analyst Ratings Breakdown

Latest MDGL, RVMD, BIIB, and ALNY Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/28/2026
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$220.00 ➝ $265.00
8/28/2026
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$240.00 ➝ $275.00
8/27/2026
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$203.00 ➝ $251.00
8/27/2026
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
Raymond James Financial, Inc. logo
Raymond James Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingStrong-Buy$248.00
8/27/2026
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
Oppenheimer Holdings, Inc. logo
Oppenheimer
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$230.00 ➝ $260.00
8/27/2026
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
Evercore Inc logo
Evercore
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform$320.00
8/27/2026
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$195.00 ➝ $280.00
8/27/2026
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
Wedbush logo
Wedbush
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$201.00 ➝ $225.00
8/27/2026
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
Truist Financial Corporation logo
Truist Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$231.00 ➝ $239.00
8/25/2026
Biogen Inc. stock logo
BIIB
Biogen
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$240.00 ➝ $260.00
8/25/2026
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
Sanford C. Bernstein logo
Sanford C. Bernstein
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform$376.00
(Data available from 8/29/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
$4.80B6.60$2.80 per share84.60$10.12 per share23.43
Biogen Inc. stock logo
BIIB
Biogen
$10.03B3.22$22.32 per share9.79$127.56 per share1.71
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
$958.40M12.87N/AN/A$22.67 per share23.54
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
$11.58M3,847.75N/AN/A$12.16 per share17.10
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
$313.75M$5.3844.0724.57N/A15.26%84.93%14.30%10/29/2026 (Estimated)
Biogen Inc. stock logo
BIIB
Biogen
$1.29B$5.6538.6713.586.908.32%11.18%6.88%10/29/2026 (Estimated)
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
-$288.28M-$12.89N/A96.17N/A-25.32%-56.65%-25.53%11/3/2026 (Estimated)
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
-$1.13B-$8.82N/AN/AN/AN/A-88.20%-57.85%11/4/2026 (Estimated)

Latest MDGL, RVMD, BIIB, and ALNY Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/5/2026Q2 2026
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
-$2.04-$3.06-$1.02-$3.06$1.77 millionN/A
7/30/2026Q2 2026
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
$1.63$1.84+$0.21$1.21$1.32 billion$1.29 billion
7/30/2026Q2 2026
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
-$2.68-$1.99+$0.69-$1.99$352.13 million$364.25 million
7/29/2026Q2 2026
Biogen Inc. stock logo
BIIB
Biogen
$2.94$3.60+$0.66$0.66$2.46 billion$2.74 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
N/AN/AN/AN/AN/A
Biogen Inc. stock logo
BIIB
Biogen
N/AN/AN/AN/AN/A
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
N/AN/AN/AN/AN/A
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
0.75
3.05
2.99
Biogen Inc. stock logo
BIIB
Biogen
0.39
1.87
1.26
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
0.65
3.20
2.94
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
0.40
11.38
11.38

Institutional Ownership

CompanyInstitutional Ownership
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
92.97%
Biogen Inc. stock logo
BIIB
Biogen
87.93%
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
98.50%
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
94.34%

Insider Ownership

CompanyInsider Ownership
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
0.86%
Biogen Inc. stock logo
BIIB
Biogen
0.25%
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
17.60%
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
7.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
2,770133.81 million132.66 millionOptionable
Biogen Inc. stock logo
BIIB
Biogen
7,500147.75 million147.39 millionOptionable
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
9023.10 million19.04 millionOptionable
Revolution Medicines, Inc. stock logo
RVMD
Revolution Medicines
250214.34 million198.05 millionOptionable

Recent News About These Companies

Truist Financial Boosts Revolution Medicines (NASDAQ:RVMD) Price Target to $239.00
 |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30990266
Revolution Medicines (NASDAQ:RVMD) Hits New 12-Month High Following Analyst Upgrade
August 29 at 1:20 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30989194
Revolution Medicines (RVMD) Made Pancreatic-Cancer History. At $47B Valuation, the Market Already Assumed It
August 28 at 5:11 PM  |  insidermonkey.comhttps://www.insidermonkey.com/blog/revolution-medicines-rvmd-made-pancreatic-cancer-history-at-47b-valuation-the-market-already-assumed-it-1824214/
Revolution Medicines Wins FDA Approval for RASONQUE in Metastatic Pancreatic Cancer
August 28 at 3:01 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/event-revolution-medicines-wins-fda-approval-for-rasonque-in-metastatic-pancreatic-cancer-2026-08-28/
Analysts Are Bullish on Top Healthcare Stocks: Revolution Medicines (RVMD), HOYA (HOCPF)
August 28 at 2:42 PM  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/RVMD/pressreleases/4308013/analysts-are-bullish-on-top-healthcare-stocks-revolution-medicines-rvmd-hoya-hocpf/
Analysts Offer Insights on Healthcare Companies: Kymera Therapeutics (KYMR), Revolution Medicines (RVMD) and Spyre Therapeutics (SYRE)
August 28 at 2:42 PM  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/RVMD/pressreleases/4308089/analysts-offer-insights-on-healthcare-companies-kymera-therapeutics-kymr-revolution-medicines-rvmd-and-spyre-therapeutics-syre/
Revolution Med risks weekly loss despite “transformative” FDA approval
August 28 at 2:42 PM  |  seekingalpha.comhttps://seekingalpha.com/news/4637945-revolution-medicines-drops-despite-first-fda-nod
Revolution Medicines (NASDAQ:RVMD) Stock Price Down 5.9% - Here's Why
August 28 at 12:59 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-revolution-medicines-nasdaq-rvmd-stock-price-down-59-heres-why-2026-08-28/
Guggenheim Forecasts Strong Price Appreciation for Revolution Medicines (NASDAQ:RVMD) Stock
August 28 at 8:59 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-guggenheim-forecasts-strong-price-appreciation-for-revolution-medicines-nasdaq-rvmd-stock-2026-08-28/
Q1 Earnings Estimate for RVMD Issued By HC Wainwright
August 28 at 7:26 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/estimates-q1-earnings-estimate-for-rvmd-issued-by-hc-wainwright-2026-08-28/
Revolution Medicines Won FDA Approval One Month After Filing. Analysts See $11.5 Billion in Peak Sales.
August 28 at 7:07 AM  |  fool.comhttps://www.fool.com/investing/2026/08/28/revolution-medicines-won-fda-approval-one-month-after-filing-analysts-see-115-billion-in-peak-sales-is-the-stock-still-a-buy-after-skyrocketing-more-than-5x/
Hsbc Holdings PLC Invests $13.46 Million in Revolution Medicines, Inc. $RVMD
August 28 at 5:28 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-hsbc-holdings-plc-invests-1346-million-in-revolution-medicines-inc-rvmd-2026-08-28/
Legal & General Group Plc Invests $71.42 Million in Revolution Medicines, Inc. $RVMD
August 28 at 5:20 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-legal-general-group-plc-invests-7142-million-in-revolution-medicines-inc-rvmd-2026-08-28/
6,534 Shares in Revolution Medicines, Inc. $RVMD Bought by Sanctuary Advisors LLC
August 28 at 5:11 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-6534-shares-in-revolution-medicines-inc-rvmd-bought-by-sanctuary-advisors-llc-2026-08-28/
Revolution Medicines (RVMD) After RASONQUE Approval Is The Valuation Story Still Intact
August 28 at 4:41 AM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/revolution-medicines-rvmd-rasonque-approval-061805357.html
Capstone Investment Advisors LLC Takes Position in Revolution Medicines, Inc. $RVMD
August 28 at 4:09 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-capstone-investment-advisors-llc-takes-position-in-revolution-medicines-inc-rvmd-2026-08-28/
Freestone Grove Partners LP Makes New $12.14 Million Investment in Revolution Medicines, Inc. $RVMD
August 28 at 4:08 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-freestone-grove-partners-lp-makes-new-1214-million-investment-in-revolution-medicines-inc-rvmd-2026-08-28/
Bamco Inc. NY Buys Shares of 12,500 Revolution Medicines, Inc. $RVMD
August 28 at 3:05 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-bamco-inc-ny-buys-shares-of-12500-revolution-medicines-inc-rvmd-2026-08-28/
How Investors Are Reacting To Revolution Medicines (RVMD) First-in-Class RASONQUE Approval In Pancreatic Cancer
August 27 at 11:41 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/investors-reacting-revolution-medicines-rvmd-231201768.html
Why the Drugmaker Behind a Pancreatic Cancer Breakthrough Stayed Independent
August 27 at 9:21 PM  |  wsj.comhttps://www.wsj.com/health/pharma/why-the-drugmaker-behind-a-pancreatic-cancer-breakthrough-stayed-independent-bc9cf607
Revolution Medicines, Inc. (RVMD) Discusses FDA Approval of RASONQUE for Metastatic Pancreatic Cancer and Implications for RAS-Driven Therapy Transcript
August 27 at 7:00 PM  |  seekingalpha.comhttps://seekingalpha.com/article/4940551-revolution-medicines-inc-rvmd-discusses-fda-approval-of-rasonque-for-metastatic-pancreatic

New MarketBeat Followers Over Time

Media Sentiment Over Time

Alnylam Pharmaceuticals stock logo

Alnylam Pharmaceuticals NASDAQ:ALNY

$237.10 +0.54 (+0.23%)
As of 08/28/2026 04:00 PM Eastern

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Biogen stock logo

Biogen NASDAQ:BIIB

$218.50 -3.00 (-1.35%)
As of 08/28/2026 04:00 PM Eastern

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Madrigal Pharmaceuticals stock logo

Madrigal Pharmaceuticals NASDAQ:MDGL

$533.76 -9.93 (-1.83%)
As of 08/28/2026 04:00 PM Eastern

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.

Revolution Medicines stock logo

Revolution Medicines NASDAQ:RVMD

$207.88 -13.27 (-6.00%)
As of 08/28/2026 04:00 PM Eastern

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas